Masimo Corporation (MASI) Stock Analysis
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $179.95, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole or limited source suppliers; Analyst target reached - limited upside remaining.
Masimo Corporation develops and manufactures noninvasive patient monitoring technologies—including SET® pulse oximetry, rainbow® multi-parameter CO-oximetry, and hospital automation platforms—sold through a direct sales force and more than 90 OEM partners including GE Healthcare... Read more
Hold if already holding. Not a fresh buy at $179.95, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole or limited source suppliers; Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Wide-moat business. Accumulate on weakness. | News modifier -1 (STRONG_BUY_WAIT → HOLD_IF_HOLDING) Score 6.0/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 49d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About Masimo Corporation
About Masimo Corporation
Masimo Corporation's Masimo SET pulse oximetry platform, available to U.S. hospitals since 1998, and the Masimo rainbow SET Pulse CO-Oximetry platform for noninvasive monitoring of hemoglobin, carboxyhemoglobin, and methemoglobin form the foundation of the company's healthcare revenue. The company completed the sale of Sound United—its non-healthcare consumer audio business—to Harman International Industries on September 23, 2025, sharpening its focus on medical technology. On February 16, 2026, Masimo entered an Agreement and Plan of Merger with Danaher Corporation at $180.00 per share in cash, with the Merger expected to close in the second half of 2026, subject to stockholder approval and regulatory clearances.
Masimo sells hardware (bedside monitors, circuit boards, handheld devices, wearable platforms) paired with proprietary single-patient-use and reusable sensors engineered to operate exclusively with Masimo SET software. This structure creates recurring consumable revenue as sensors are consumed per patient encounter. More than 90 OEM partners—including GE Healthcare, Hillrom, Mindray, Philips, Physio-Control, and Zoll—incorporate Masimo SET or rainbow SET circuit boards into their multiparameter monitors. The company also markets hospital automation and connectivity solutions (Patient SafetyNet, iSirona, UniView, Iris Gateway) that integrate third-party device data into electronic medical records. A Cross-Licensing Agreement with Willow Laboratories (formerly Cercacor Laboratories) governs the rainbow technology and, by its terms, limits Masimo's ability to commercialize new products and additional applications for its Masimo SET and licensed rainbow technologies.
Show full overview
The Willow Laboratories Cross-Licensing Agreement imposes a structural ceiling on product scope: the 10-K discloses that the agreement would require Masimo to assign to Willow certain products and technologies relating to the monitoring of non-vital sign parameters. Separately, the pending Danaher merger carries a $305 million termination fee payable to Danaher if the Merger Agreement is terminated in certain circumstances, including if the company accepts a Superior Proposal—a provision that could weigh on any competing bid valuation. Key materials and components are sourced from sole or limited source suppliers, and the 10-K warns that inability to obtain these materials would prevent product delivery to customers.
See also: Healthcare · Medical Devices
From Masimo Corporation's most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-06-17Recent Developments — Masimo Corporation
Latest news
- NEWS Sirius XM Holdings Will Replace Masimo Corp. In The S&P MidCap 400 Effective Prior To The Opening Of Trading On Thursday — benzinga Jun 8, 2026 negative
- NEWS Masimo Stockholders Approve Merger Agreement With Danaher, Mobius Merger Sub — benzinga May 4, 2026 positive
- NEWS Masimo's Appeal Rejection, M5 Chip Push, China Smartphone Growth, Foldable iPhone: This Week In Appleverse — benzinga Apr 19, 2026 negative
- NEWS Apple Scores Key Win As Trade Commission Rejects Masimo's Bid To Reinstate Apple Watch Import Ban — benzinga Apr 18, 2026 negative
Generated 2026-06-17T08:56:48Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMProductMasimo SET® and rainbow SET® platforms10-K Item 1A: 'We currently derive a significant portion of our revenue from our Masimo SET® platform, Masimo rainbow SET® platform and related products.'
- HIGHSuppliersole or limited source suppliers10-K Item 1A: 'If we are unable to obtain key materials and components from sole or limited source suppliers, we will not be able to deliver our products to customers.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $179.95, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole or limited source suppliers; Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Wide-moat business. Accumulate on weakness. | News modifier -1 (STRONG_BUY_WAIT → HOLD_IF_HOLDING) Target $176.39 (-2.0%), stop $179.23 (−0.4%), A.R:R -1.0:1. Score 6.0/10, moderate confidence.
Take-profit target: $176.39 (-2.0% upside). Target $176.39 (-2.0%), stop $179.23 (−0.4%), A.R:R -1.0:1. Stop-loss: $179.23.
Concentration risk — Supplier: sole or limited source suppliers; Analyst target reached - limited upside remaining; Near 52-week high (0.0% away).
Masimo Corporation trades at a P/E of 44.4 (forward 26.8). TrendMatrix value score: 4.7/10. Verdict: Hold.
15 analysts cover MASI with a consensus score of 3.5/5. Average price target: $180.
What does Masimo Corporation do?Masimo Corporation develops and manufactures noninvasive patient monitoring technologies—including SET® pulse oximetry,...
Masimo Corporation develops and manufactures noninvasive patient monitoring technologies—including SET® pulse oximetry, rainbow® multi-parameter CO-oximetry, and hospital automation platforms—sold through a direct sales force and more than 90 OEM partners including GE Healthcare and Philips. The company completed the sale of its Sound United consumer audio business to Harman International in September 2025 and entered a merger agreement with Danaher Corporation at $180 per share in February 2026, expected to close in the second half of 2026.